Company
Company

Relevant Interviews, Webinar and Trial Updates posted by CRISPR Medicine News.

Always stay updated with the free CMN Newsletter.

Tome Bioscience Inc.

Company Type: Therapeutic development

Main focus: New treatments for patients via the development of novel cell and integrative gene therapies

Company stage: Pre-clinical

Diseases: Monogenic liver diseases and autoimmune diseases

Genome-editing tool: Programmable Genomic Integration (PGI), using CRISPR-Cas9

Funding stage: Series A

Location: Watertown, Massachusetts, USA

Website: https://tome.bio/

Pipeline:

Partners:

Tome Biosciences, Inc. is the developer of the programmable genomic integration (PGI) technology that allows for site-specific insertion of genetic sequences of any size into the genome. PGI combines the site-specificity of CRISPR/Cas9 with enzymes capable of inserting sequences without the need for double-strand DNA breaks. The company plans to develop integrative gene therapies for monogenic liver diseases and cell therapies for autoimmune diseases.

Tags

HashtagTome Biosciences

Company: Tome Bioscience Inc.
close
Search CRISPR Medicine